Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Gilead Sciences, Inc.
22 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Announcement
AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious Disease
PR-M06-19-NI-017
Appointment
Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer
PR-M05-19-NI-081
HIV
Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
PR-M05-19-NI-038
Leadership
Changes Coming to Gilead Under New Top Exec
PAO-M05-19-NI-016
Financial Results
Gilead Sciences Announces First Quarter 2019 Financial Results
PR-M05-19-NI-018
Milestone Payment
Agenus Milestone Triggers $7.5M Payment from Gilead
PR-M03-19-NI-047
Immuno-oncology
Gilead Invests in Immuno-oncology
PAO-M01-19-NI-001
Appointment
Roche Exec Moves to Gilead
PAO-M12-18-NI-010
Collaboration
TARGET PharmaSolutions® to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences
PR-M11-18-NI-089
Generics
Gilead Makes Move to Launch Early Generics
PAO-M10-18-NI-001
HIV Diagnoses
Gilead Announces New Data on the Impact of Truvada® for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States
PR-M07-18-NI-087
Inflammatory Disease
Gilead Sciences and Verily Life Sciences LLC Enter Collaboration, Hope to Better Understand Inflammatory Diseases
PAO-M05-18-NI-002
Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope
PR-M03-18-NI-021
Appointment
Gilead Sciences Announces Senior Management Change
PR-M02-18-NI-101
Oncology
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
PR-M02-18-NI-95
CAR-T
Pfizer Joins Gilead in CAR-T Development
PAO-M01-18-NI-044
Acquisition
Gilead’s new Kite Subsidiary To Buy CAR-T Cell Therapy Company Cell Design Labs
PAO-M01-18-NI-001
Research
Gilead Makes $100 Million Commitment to Fighting HIV/AIDs
PAO-M12-17-NI-038
Drug Development
U.S. Patient Receives Kite’s Yescarta CART-T Therapy
PAO-M12-17-NI-008
Acquistion
Kite Pharma Acquisition by Gilead Finalized
PAO-M10-17-NI-017
Acquisition
Gilead Sciences to Fly Kite Pharma for $11.9 Billion
PAO-M08-17-NI-036
FDA
Vosevi Hepatitis C Treatment Approved by the FDA
PAO-M07-17-NI-028
